Journal
IMMUNOLOGICAL REVIEWS
Volume 294, Issue 1, Pages 48-62Publisher
WILEY
DOI: 10.1111/imr.12839
Keywords
arthritis; CARD8; gout; inflammasome; innate immunity; NLRP3
Categories
Funding
- Institute of Rheumatology Research
- Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung [310030_173152]
- ZonMw [452183005]
- Dutch Research Council (NWO)
- Swiss National Science Foundation (SNF) [310030_173152] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Inflammasomes are intracellular multiprotein signaling platforms that initiate inflammatory responses in response to pathogens and cellular damage. Active inflammasomes induce the enzymatic activity of caspase-1, resulting in the induction of inflammatory cell death, pyroptosis, and the maturation and secretion of inflammatory cytokines IL-1 beta and IL-18. Inflammasomes are activated in many inflammatory diseases, including autoinflammatory disorders and arthritis, and inflammasome-specific therapies are under development for the treatment of inflammatory conditions. In this review, we outline the different inflammasome platforms and recent findings contributing to our knowledge about inflammasome biology in health and disease. In particular, we discuss the role of the inflammasome in the pathogenesis of arthritic diseases, including rheumatoid arthritis, gout, ankylosing spondylitis, and juvenile idiopathic arthritis, and the potential of newly developed therapies that specifically target the inflammasome or its products for the treatment of inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available